GLP-1 Agonists Market Size is valued at USD 43.1 billion in 2024 and is predicted to reach USD 260.1 billion by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034.
GLP-1 agonists, known to be beneficial in treating type 2 diabetes, are glucagon-like peptide-1 receptor agonists. The action of GLP-1 RAs is to enhance insulin synthesis and inhibit glucagon secretion by activating GLP-1 receptors. While all GLP-1 RAs have the exact mechanism of action, there are differences in formulation, dose, injection technique, and administration. The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead. These drugs help manage type 2 diabetes by increasing insulin production and decreasing glucagon release, improving blood sugar control and cardiovascular health. GLP-1 agonists have demonstrated potential in managing weight, a crucial motivation. Because type 2 diabetes and obesity are frequently co-occurring, this technique is very helpful in managing both conditions. Because these drugs lead to weight loss, they appeal to patients and doctors. Furthermore, developing new treatments is anticipated to fuel the growth of the GLP-1 receptor agonist market.
However, the market development is hampered by the high-cost criteria for the safety and health of the GLP-1 agonists market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high GLP-1 agonists because GLP-1 agonists are expensive, which can prevent some patients from getting the treatment they need. There may not be extensive use due to this financial obstacle and worries about injections. There may not be extensive use due to this financial obstacle and worries about injections. One potential future hurdle for the growth of the market for glucagon-like peptide 1 (GLP-1) agonists is the availability of suitable insurance. As a result of COVID-19-related travel restrictions and lockdowns, the worldwide supply chain for GLP-1 receptor agonists was disrupted. Because of this, the healthcare business was hit hard by the COVID-19 pandemic, which disrupted the supply chain and compromised processes ranging from ingredient procurement to final delivery.
Competitive Landscape
Some of the major key players in the GLP-1 agonists market are:
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Novo Nordisk
- Boehringer Ingelheim
- Twist Bioscience Corporation
Market Segmentation:
The GLP-1 agonists market is segmented based on product, application, route of administration and distribution channel. As per the Product, the market includes Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other Products. Whereas, by Application, the market is divided into Type 2 Diabetes Mellitus, and Obesity. Acccording to the Route of Administration, the market is segmented into Parenteral, and Oral. Distribution channel includes hospital pharmacies, retail pharmacies, and online pharmacies.
Retail Pharmacies Segment To Witness Growth At A Rapid Rate
Retail pharmacies make up the bulk of GLP-1 agonists usage because participating in retail pharmacies in clinical trials provides more individualized patient care. As the initial point of contact for many patients seeking medical assistance, retail pharmacists can be crucial in identifying individuals suited for clinical trials, particularly in nations like the US, Germany, the UK, China, and India.
The North American GLP-1 Agonists Market Holds A Significant Revenue Share In The Region.
The North American GLP-1 agonists market is expected to register the highest market share in revenue in the near future. The area has a well-developed healthcare infrastructure, major actors are present, the disease prevalence is high, and investments in research and development for novel medications to treat diabetes and obesity are expanding. In addition, Asia Pacific is projected to increase in the global GLP-1 agonists market because diabetes and other linked illnesses are becoming more common. With more generic pharmaceuticals hitting the market, the glucagon-like peptide 1 (GLP-1) agonists market is expected to develop in the region.
GLP-1 Agonists Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 43.1 Bn |
|
Revenue Forecast In 2034 |
USD 260.1 Bn |
|
Growth Rate CAGR |
CAGR of 19.9% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Application, Route Of Administration, Molecule, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; Japan; South Korea; Southeast Asia |
|
Competitive Landscape |
Eli Lilly and Company, Sanofi, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Twist Bioscience Corporation |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
